FILTER
LATEST INTERVIEWS
Tomás Buttazzoni
GENERAL MANAGER, TECHNOSTEEL
Technosteel is a Chilean company developing solutions for conveyor belts and equipment for mining exploration.
Anthony Capobianco
FOUNDER AND PRESIDENT, STEMSYNERGY THERAPEUTICS
StemSynergy Therapeutics (SSTI) is a biotechnology company focused on discovering drugs that target biomolecules and cellular processes fundamental to cancer.
Roberto Santos
CEO, UNIGEL
Unigel explains the impact of COVID-19 on Brazil’s chemical sector and why there is confidence that the industry is recovering.
Doug Ramshaw
PRESIDENT, MINERA ALAMOS
Minera Alamos outlines progress at its Santana gold project in Mexico.
Segun Lawson
CEO, THOR EXPLORATIONS
Thor Explorations is reviving Nigeria’s gold mining industry with the construction of its Segilola gold project.
Michael Bennett
PRESIDENT & CEO, ALTAMIRA GOLD
Altamira is making the transition from an exploration to a production company at the perfect time for the price of gold, and an opportune time in Brazil – a pro-mining country that has streamlined its permitting processes.
Theo Yameogo
CO-LEADER – MINING AND METALS CANADA, ERNST & YOUNG
EY explains to GBR how the COVID-19 pandemic must accelerate the adoption of digitalization and other disruptive technologies by the mining industry.
Joaquín Villarino
PRESIDENT, CONSEJO MINERO
Consejo Minero explains the issues that are currently preoccupying Chile’s miners.
Kevin Fell
GROUP CEO, CLEAN MINING
Clean Mining is working to transform gold production worldwide with a new mineral processing technology that eliminates cyanide and mercury in the gold recovery process.
Eduardo Nilo
GENERAL MANAGER, METSO CHILE
Metso speaks to GBR about its intentions for the Chilean market.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
